---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-26-000107"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2026-07-13T20:25:14+00:00"
generated_at: "2026-07-13T20:26:08.632960+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics appoints two new independent directors, expands board to nine

## Summary
- Board size increased from 7 to 9; Robert Iannone, M.D. and Flavia Borellini, Ph.D. appointed as Class I and Class II directors respectively.
- Iannone joins R&D Committee; Borellini appointed chair of R&D Committee.
- Each new director receives annual retainer of $40,000, plus committee fees; each granted option for 60,000 shares vesting over 3 years.
- Both directors determined independent under SEC and Nasdaq rules; no material transactions with company.

## SEC filing metadata
- accession: 0001746473-26-000107
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2026-07-13T20:25:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/0001746473-26-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/plrx-20260709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-26-000107
- JSON: https://secwatch.observer/filing/0001746473-26-000107.json
- Plain text: https://secwatch.observer/filing/0001746473-26-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.